Two of the newer classes of drugs, glucagon like peptide 1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 (SGLT2) inhibitors, used in type 2 diabetes treatment, have been seen to reduce ResR [41,50,51,52,53,54]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.